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Parathyroid Hormone-Related Disorders
John P. Bilezikian, MD,* and T.J. Martin, MD^

Pathogenesis of Parathyroid Hypersecretion

T

he pathogenesis of primary hyperparathyroidism is the subject of several different experimental approaches which
were presented in the first part of this session. Genetic control
of the hyperparathyroid secretory state could be due to a single
lesion in a single cell giving rise to a monoclonal origin of the
hyperparathyroidism. Altematively, the hyperparathyroid gland
could have its genetic roots in a multicellular process in which
the tissue responds to a variety of more pervasive extemal influences such as humoral factors, circulating antibodies, or cell-tocell spread of a tumorigenic virus. Molecular genetics have
helped to begin to test further the hypothesis that the single adenomatous parathyroid gland is a monoclonal neoplasm whereas
the form of hyperparathyroidism due to four-gland hyperplasia
is a polyclonal disorder.

Approaches to the clonality of human tumors and their
application to parathyroid adenomas
Amold and Kronenberg (1) have applied the technique of restriction fragment length polymorphism to examine this issue.
Eight of 43 adenomas and five of 23 hyperplastic glands were
found to be heterozygous for the BamHI/HPRT polymorphism
and thus available for study by this technique. Six of eight adenomas showed clear loss of one allele, consistent with monoclonality, while all five hyperplastic parathyroids showed relative nonpreferential Hpall cleavage consistent with polyclonality. Certain technical limitations of this approach require
that these results be confirmed by other molecular tests as well as
by more classical genetic approaches. The data, however, do indicate that a majority of parathyroid adenomas are monoclonal
neoplasms and suggest a fundamental difference in their pathogenesis as compared to the multiglandular form of primary
hyperparathyroidism.
Physiology and pathophysiology of Ca+ +-regulated
parathyroid hormone release
The parathyroid cell is an unusual secretory cell in terms of its
relationship to calcium. Whereas most secretory cells are stimulated by cellular calcium (classical stimulus-secretion coupling), the parathyroid cell is inhibited by cellular calcium. In
normal parathyroid tissue, the relationship between parathyroid
hormone secretion and extracellular calcium is steep with the
major element of control by calcium being exerted over the
physiological range of calcium (1 to 1.25 mM). In primary hyperparathyroidism, sensitivity to control by calcium is reduced
both by virtue of the increased number of parathyroid cells and
by an increase in the "set-point" for calcium-regulated parathyroid hormone release. The work presented by Brown et al (2)
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has begun to provide a conceptual framework within which altered regulation by calcium in primary hyperparathyroidism can
be understood. The studies have emphasized the physiological
regulation of normal parathyroid cells. As previously shown by
Fitzpatrick and Aurbach, pertussis toxin blocks the inhibitory
effects of high extracellular calcium on parathyroid hormone release, suggesting a role for a guanine nucleotide binding protein
in transducing the signal generated by calcium. However, the
rise in inositol phosphates and cellular calcium induced by extracellular calcium is not inhibited by pertussis toxin, suggesting that at this step at least the putative G protein is not a pertussis toxin substrate. A number of other potentially important
physiologically relevant agonists besides calcium have been
shown to regulate parathyroid hormone secretion. Biogenic
amines such as dopamine, stimulators of protein kinase C such
as phorbol esters, and guanine nucleotides are all potential secretagogues that may not be mediated by changes in cellular calcium or cyclic AMP. In hyperparathyroidism the abnormal regulation by calcium of parathyroid hormone can be best described
by pathophysiological changes in the maximal secretory rate at
low calcium concentrations, the set-point itself, the slope ofthe
curve at its midpoint, and the minimal secretory rate at high calcium concentration.

Multiple endocrine neoplasia type 1: Role of a circulating
growth factor in parathyroid cell hyperplasia
Insight into the pathophysiological disturbance of the primary
hyperparathyroidism associated with multiple endocrine neoplasia type 1 (MEN-1) has been made by Brandi et al (3). They
hypothesized that a substance stimulating parathyroid cell proliferation is involved in the pathophysiology of the disorder.
Plasma from MEN-1 was shown to be selectively mitogenic for
parathyroid cells. Plasma from other hyperparathyroid syndromes was considerably less mitogenic. Characterization of the
factor shows it to have an apparent molecular weight of 50 kilodaltons and to share certain properties of thefibroblastgrowth
factor-related proteins. Evidence has recently been obtained to
suggest that the target cell of this growth factor appears to be the
endothelial cell ofthe parathyroid vasculature. The parathyroid
epithelial cell and other endothelial cells do not show reactivity
to the parathyroid growth factor. How this factor is released into
the circulation, its exact relationship to FGF-like proteins and/or

•College of Physicians and Surgeons, New York.
tDepartment of Medicine. Repatriation General Hospital. Victoria, Australia.
Address correspondence to Dr Bilezikian. College of Physicians and Surgeons 630 W
168th St/P& S 8-405. New York. NY 10032.

PTH-Related Disorders—Bilezikian & Martin

159

oncogene products related to the FGF family, as well as its
source are all questions for further intense investigation.

Most, but not all, patients manifesting a reduction in Gsalpha
activity show a decrease in messenger RNA by Northem blot
analysis.

Pseudohypoparathyroidism
This classic genetic disorder of calcium metabolism has distinctive characteristics: short stature, round facies, short neck,
foreshortened metacarpal and metatarsal bones, a tendency to
mental retardation, and calcifications in the basal ganglia
(Albright hereditary osteodystrophy or pseudohypoparathyroidism, type la). In contrast to true hypoparathyroidism,
the hypocalcemia is accompanied by elevated immunoreactive parathyroid hormone levels; hence the designation,
pseudohypoparathyroidism. The salient biochemical feature of
pseudohypoparathyroidism, la, resistance to the actions of parathyroid hormone, is seen by the lack of aphosphaturic and cyclic
AMP response to parathyroid hormone. Pseudohypoparathyroidism, type Ib, is identical to type la except that Albright
hereditary osteodystrophy is not present and other hormone resistant states, typical of the la phenotype, are not seen. Patients
do have the biochemical abnormalities. After Albright described pseudohypoparathyroidism, he observed a patient with
the typical body habitus of pseudohypoparathyroidism but without evidence for hypocalcemia or target organ resistance. In his
attempt to distinguish this variant from classical pseudohypoparathyroidism, Albright dubbed it pseudopseudohypoparathyroidism. Pseudohypoparathyroidism and pseudopseudohypoparathyroidism clearly belong to the same genetic family as
evidenced by family trees that contain both forms of the disorder, by selected patients whose biochemical profile has been
known to cross over to the other, and by the molecular basis of
the disorder.
G proteins as signal transducers
Important clues to the defect in pseudohypoparathyroidism
were gained by observations of Levine (4) as well as by several
other groups. The constellation of hormone resistant states included in the syndrome involves the adenylate cyclase messenger system. A site common to all hormones that utilize adenylate cyclase is the guanine nucleotide binding protein, Gs,
that links their different receptors to the catalytic unit of adenylate cyclase. Patients with Albright hereditary osteodystrophy
(pseudohypoparathyroidism, type la) demonstrate a 50% reduction in the alpha subunit of Gs. There does not appear to be any
gross gene deletions or rearrangements of the gene encoding
Gsalpha. Levels of the alpha subunit of the inhibitory guanine
nucleotide binding protein, Gi, are normal. Despite the enthusiasm generated by this observation, reduced Gsalpha levels do
not entirely account for the syndrome. Patients with pseudopseudohypoparathyroidism in which the typical physiognomy is
not accompanied by hormone resistance nevertheless do have
reduced Gsalpha levels. Only patients with the classical disorder, but not all, have the reduction in Gsalpha. Patients with type
Ib and parathyroid resistance in the absence of any other hormone resistance have normal levels of Gs, implicating that this
isolated hormone resistant state might be due to a defect in the
parathyroid hormone receptor per se. Even within the group of
patients who show reductions in Gsalpha, there is heterogeneity.
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Pseudohypoparathyroidism: Studies of the pathogenesis of
parathyroid hormone resistance
In view ofthe fact that the G protein abnormality does not appear to account entirely for the syndrome, Goltzman et al (5) as
well as others have examined the possibility that characteristics
of parathyroid hormone per se might contribute to the manifestations of functional hypoparathyroidism in pseudohypoparathyroidism. Characteristics of circulating parathyroid hormone (PTH) were examined in three patients with the classical
syndrome. In the plasma of these patients were elevations in immunoreactive PTH but reductions in biologically active PTH as
determined by cytochemical bioassay. In addition, the plasma
of these patients appeared to contain an inhibitor of exogenous,
biologically active PTH by two in vitro bioassays. The biochemical profile of immunoreactive PTH in patient plasma
showed differences from normal plasma in that the bulk of the
circulating immunoreactivity in pseudohypoparathyroidism
consisted of more hydrophobic moieties. These results are consistent with the presence of an alteration in parathyroid hormone
metabolism within the parathyroid gland in pseudohypoparathyroidism. The defect in Gsalpha might accommodate
such an hypothesis because the parathyroid cell presumably also
is impaired in this regard. Goltzman et al (5) have pursued this
possibility further by investigating an experimental model of
parathyroid hormone resistance in the vitamin D deficient rat.
Elevated levels of parathyroid hormone in this syndrome are associated with post-PTH receptor reductions in Gsalpha that extend to other hormones that utilize the adenylate cyclase system.
When these observations are viewed together, they suggest that
reduced levels of Gs are not necessarily causally related to hormone resistance in pseudohypoparathyroidism and also that the
underlying mechanism for the various forms of pseudohypoparathyroidism are likely to be heterogeneous.

Primary Hyperparathyroidism
Primary hyperparathyroidism: The surgically
cured patient
Primary hyperparathyroidism has become a relatively common endocrine disorder due to the widespread use of multichannel autoanalyzers in medicine. The increased incidence has
been accompanied by a marked reduction in the presence of obvious signs and symptoms related to the hyperparathyroid state.
These observations have led to a change in the therapeutic
approach to primary hyperparathyroidism. Patients are not always subjected to parathyroidectomy because many are
asymptomatic and do not appear to be suffering adverse consequences of the disease. In an effort to gain greater insight into
the modem-day presentation of primary hyperparathyroidism,
Ljunghall and associates (6) reviewed an experience of 570 patients who underwent parathyroid exploration between 1965 and
1984. The average postoperative follow-up period was seven
years. The average age was 59, with women predominating over
men by 3:1. Adenomas were found in 80%. The overwhelming
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majority of patients with adenomatous disease became normocalcemic (93%). Recurrences, however, tended to increase
with time for both adenomatous and hyperplastic disease.
Postoperative results focused on the relatively nonspecific aspects of primary hyperparathyroidism because classical bone
and stone disease have become relatively infrequent. A fair
number of patients, however, did report postoperative improvement in complaints such as easy fatigability, memory, concentrating ability, depression, and several neuropsychiatric
complaints. Ljunghall et al (6) also assessed other disorders believed to be associated with primary hyperparathyroidism such
as hypertension and diabetes mellitus. They found little evidence for a pathophysiological association between either disease and primary hyperparathyroidism in that successful parathyroid surgery does not appear to alter the hypertension or the
diabetes. They also addressed the epidemiological evidence for
increased mortality from cardiovascular and malignant disease
in primary hyperparathyroidism.

be relatively preserved. Only 13% of patients showed a reduction in trabecular bone mineral density to less than 80% of expected. These results were confirmed by results of the percutaneous bone biopsy in which the vast majority of patients
(84%) had mean cortical width determinations below expected,
whereas an equivalently large number of patients (85%) showed
trabecular bone volume greater than average. These early results
indicate that the routine assignment of patients with primary hyperparathyroidism to an asymptomatic cohort, if they don't
show clinically apparent complications, should be tempered by
the likely possibility of skeletal involvement after more detailed
testing. The results raise questions about the definition of
asymptomatic primary hyperparathyroidism and call for additional long-term studies in order to define better the risk factors
for complications of this disease.

Primary hyperparathyroidism in the 1980s
In examining the asymptomatic patient with primary hyperparathyroidism in a prospective long-term study, two key questions are being addressed (7): In mild, asymptomatic primary
hyperparathyroidism, can other evidence for parathyroid bone
disease be discovered upon more detailed evaluation? Which
asymptomatic patients are at risk for developing complications
of primary hyperparathyroidism? Among the 67 patients evaluated so far, the average age is 55, with women predominating over men by 2.5:1. The biochemical indices are typical
with mild hypercalcemia (11.1 ± 0.1 mg/dL) and elevations in
parathyroid hormone by radioimmunoassay. "Mid-molecule"
radioimmunoassay and "intact" immunoradiometric assays
show frankly elevated values in well over 90% of patients. No
patient has radiologically overt parathyroid bone disease; 19%
of patients had nephrolithiasis. Only one patient showed classical neuromuscular disease of primary hyperparathyroidism.
By bone densitometry, patients showed reductions in bone
mineral density that were preferential to cortical bone. The distal radius, consisting of predominantly cortical bone, showed a
reduction in bone mineral density to less than 80% of expected
in 58% of the patients. In contrast, trabecular bone appeared to

1. Arnold A, Kronenberg HM. Approaches to the clonality of human tumors
and their application to parathyroid adenomas. In: Kleerekoper M. Krane SM.
eds. Clinical disorders of bone and mineral metabolism. New York: Mary Ann
Liebert, Inc, 1989 (in pre.ss).
2. Brown EM, Chen CJ, Leboff MS. Physiology and pathophysiology of
Ca^ +-regulated PTH release. In: Kleerekoper M, Krane SM, eds. Clinical disorders of bone and mineral metabolism. New York: Mary Ann Liebert, Inc, 1989
(in press).
3. Brandi ML, Zimering MB, Marx SJ, et al. Multiple endocrine neoplasia
type I: Role of a circulating growth factor in parathyroid cell hyperplasia. In:
Kleerekoper M. Krane SM, eds. Clinical disorders of bone and mineral metabolism. New York: Mary Ann Liebert, Inc, 1989 (in press).
4. Levine MA. G proteins as signal transducers. In: Kleerekoper M, Krane
SM, eds. Clinical disorders of bone and mineral metabolism. New York: Mary
Ann Liebert, Inc, 1989 (in press).
5. Goltzman D. Mitchell JA, Hendy GN. Pseudohypoparathyroidism: Studies of the pathogenesis of parathyroid hormone resistance. In: Kleerekoper M,
Krane SM, eds. Clinical disorders of bone and mineral metabolism. New York:
Mary Ann Liebert. Inc. 1989 (in press).
6. Ljunghall S, Jobom C, Palmer M, Rastad J, Akerstrom G. Primary hyperparathyroidism: The surgically cured patient. In: Kleerekoper M, Krane SM.
eds. Clinical disorders of bone and mineral metabolism. New York: Mary Ann
Liebert. Inc, 1989 (in press).
7. Bilezikian JP, Silverberg SJ, Shane E. Primary hyperparathyroidism in the
1980s. In: Kleerekoper M. Krane SM, eds. Clinical disorders of bone and mineral metabolism. New York: Mary Ann Liebert, Inc, 1989 (in press).

References

Henry Ford Hosp Med J—Vol 36, No 3. 1988

PTH-Related Disorders—Bilezikian & Martin

161

